Immuno-Oncology | Specialty

Vaccine Promotes Immune Response in Ovarian Cancer

November 19th 2012

Interim data from a phase II clinical study of the dendritic cell vaccine CVac in patients with epithelial ovarian cancer showed promising signs of improving PFS compared with the observational standard of care.

Five PD-1-Related Questions for Suzanne L. Topalian, MD

November 5th 2012

Suzanne L. Topalian, MD, has led clinical development of monoclonal antibodies to treat patients with melanoma and other solid tumors, including those targeting the PD-1 T cell co-receptor.

Dr. Rotkowitz Describes Challenges Facing Immunotherapy

November 2nd 2012

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Targeting PD-1: Immune Checkpoint Strategy Finds New Spot to Arrest Cancer

October 31st 2012

Increasing evidence suggests that the ability to outsmart the body's immune response represents a hallmark of tumor development.

Dr. Rotkowitz on Ipilimumab Plus Dacarbazine for Melanoma

October 26th 2012

Michael Rotkowitz, MD, from Cancer Treatment Centers of America, discusses a phase III trial that examined ipilimumab plus dacarbazine for patients with metastatic melanoma.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Robust Sipuleucel-T Immune Activity Is Detailed in Pooled Data Analysis

October 24th 2012

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.

Dr. Ribas on Combining Vemurafenib and Ipilimumab

October 9th 2012

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

New Metastatic Melanoma Therapies Create Hope for Patients, Key Role for Oncology Nurses

October 8th 2012

The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.

Long-Term Data Show Significant Improvement in Survival With Ipilimumab in Melanoma

October 3rd 2012

Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

September 19th 2012

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Dr. Petrylak Explains How Sipuleucel-T Impacts Survival

September 7th 2012

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.

Researchers Determine Immune Parameters that Lead to Better Survival in Patients who Receive Sipuleucel-T

August 17th 2012

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

Dr. Sandler on Immunotherapies to Treat Lung Cancer

August 2nd 2012

Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer

ï»¿Combining Novel Therapeutics: Strategies Emerge for Employing Both New Options in Melanoma

July 26th 2012

It is difficult to overstate the excitement surrounding the development of two new effective therapeutic strategies in the management of metastatic melanoma.

Sipuleucel-T Studies Support Earlier Use, Reveal Potential Biomarker

July 25th 2012

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Black Men With Advanced Prostate Cancer May Benefit From Sipuleucel-T

July 18th 2012

Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Fong Discusses Immune Response to Sipuleucel-T

July 10th 2012

Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Topalian on the PD-1 Immunotherapy BMS-936558

June 22nd 2012

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.